Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc. (Nasdaq: TECX) is a clinical-stage biotechnology company discovering and developing therapeutic proteins and antibodies that modulate G-protein-coupled receptors (GPCRs). Its proprietary GEODe platform is designed to support biologic drug discovery against GPCR targets. The company’s lead… From the company’s description.
In fiscal 2025, Tectonic Therapeutic, Inc. reported a net loss of $74.15M. Operations used $60.08M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Tectonic Therapeutic, Inc. does
In the company’s own words
Tectonic Therapeutic, Inc. (Nasdaq: TECX) is a clinical-stage biotechnology company discovering and developing therapeutic proteins and antibodies that modulate G-protein-coupled receptors (GPCRs). Its proprietary GEODe platform is designed to support biologic drug discovery against GPCR targets. The company’s lead candidate, TX45, is an Fc-relaxin fusion molecule that activates the RXFP1 receptor and is being studied for pulmonary hypertension associated with heart failure with preserved ejection fraction and interstitial lung disease. TX2100, an antibody antagonist of the APJ receptor, is in early clinical development for hereditary hemorrhagic telangiectasia, a genetic bleeding disorder. A third program is developing a GPCR-modulating bispecific candidate for fibrotic diseases. Tectonic has no reportable business segments described; its activities center on research and development, and it has not established commercial or distribution capabilities. It relies on third-party manufacturers for clinical and potential future commercial production. The company’s programs are in clinical or discovery-stage development, with no marketed products described.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1681087
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Tectonic Therapeutic, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Tectonic Therapeutic, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Tectonic Therapeutic, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Tectonic Therapeutic, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Tectonic Therapeutic, Inc.'s last four quarterly filings that the numbers alone won't show?”